Neopterin: A Promising Candidate Biomarker for Severe COVID-19
Open Access
- 1 February 2021
- journal article
- review article
- Published by Taylor & Francis Ltd in Journal of Inflammation Research
- Vol. ume 14, 245-251
- https://doi.org/10.2147/jir.s290264
Abstract
Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection has rapidly spread across the world since its first emergence in China in late 2019. It is a major public health concern with no effective treatct 3ments. The immunopathology of SARS-CoV-2 is associated with an excessive inflammatory response. Macrophage activation syndrome (MAS) is also associated with the severity of the disease in SARS-CoV-2-infected patients. Neopterin is a macrophage activation marker produced by monocytes and macrophages upon activation by interferon-gamma (IFN-γ). Neopterin is a well-established marker in a variety of diseases, and recent evidence indicates that it could be helpful in early prediction of the severity of COVID-19 disease and serve as a prognostic marker. Here, we outline the role of macrophage activation syndrome in the pathogenesis of SARS-CoV-2 and suggest that neopterin could be used as a biomarker for progression of COVID-19.This publication has 60 references indexed in Scilit:
- Association between Serum Neopterin and Inflammatory Activation in Chronic Kidney DiseaseMediators of Inflammation, 2012
- Detection of serum neopterin for early assessment of dengue virus infectionJournal of Infection, 2006
- Gamma Interferon Is Dispensable for Neopterin Production In VivoClinical and Vaccine Immunology, 2005
- Serum neopterin for early assessment of severity of severe acute respiratory syndromeClinical Immunology, 2005
- Serum Neopterin, an Immune Activation Marker, Independently Predicts Disease Progression in Advanced HIV-1 InfectionClinical Infectious Diseases, 2005
- Neopterin in HIV-1 infectionMolecular Immunology, 2005
- Macrophage activation syndromeCurrent Opinion in Rheumatology, 2002
- Inhibition of Allogeneic T Cell Proliferation by Indoleamine 2,3-Dioxygenase–expressing Dendritic CellsThe Journal of Experimental Medicine, 2002
- Induction of inducible nitric oxide synthase expression by neopterin in vascular smooth muscle cellsFEBS Letters, 1995
- Immune response-associated production of neopterin. Release from macrophages primarily under control of interferon-gamma.The Journal of Experimental Medicine, 1984